Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026

Contributed by: PR Newswire

Tags

LUNDBECK-Vyepti-new

More Like This

Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine

Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine

Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference

Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine